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Abstract 
Objective: Glucosamine is widely used to improve the symptoms and to delay the structural progression of osteo‑
arthritis. However, its efficacy in osteoarthritis has been controversial and its underlying mechanism of action remains 
unclear. The aim of this study was to investigate the effects of glucosamine and the underlying mechanisms in human 
chondrocytes.
Methods: Chondrocytes from normal human articular cartilage were treated with glucosamine (10–100 mM). 
Subsequently, cell death was analyzed by Annexin V staining and FACS and mitochondrial function was studied by 
measuring the mitopotential. Peroxisomal function was analyzed by BODIPY staining, and gene expression of PMP70 
and acyl‑CoA oxidase 1, by real‑time PCR. Total lipids were analyzed by gas chromatography/mass spectrometry. 
Autophagy activation was determined by western blotting of beclin and light chain 3B. Autophagosome formation 
was analyzed by introduction of green fluorescent protein (GFP) LC3, and pexophagy was determined by introduction 
of mRFP‑EGFP‑SKL plasmids.
Results: Treatment of chondrocytes with glucosamine exerts exposure time‑dependent dual effects on apoptosis/
autophagy. Short time exposure of glucosamine to chondrocytes activated autophagy, pexophagy, and peroxidation. 
On the other hand, long time exposure of glucosamine had opposite effects, namely accumulation of very long chain 
fatty acids and peroxisomal dysfunction.
Conclusion: We highlight the dual role of glucosamine in apoptosis/autophagy in human chondrocytes depending 
on exposure time. Although further research is required to fully understand the dual effects of glucosamine, dosage 
and duration of glucosamine treatment are clear contributing factors towards the line of beneficial reward‑to‑risk 
action.
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Background
Osteoarthritis (OA), one of the most disabling arthritic 
conditions, affects not only cartilage, but also induces 
metabolic and structural modifications of the subchon-
dral bone and the synovial membrane [1]. Despite the 
increasing number of OA patients, to date no cure for 
this disease has been found. Currently, the management 
of OA consists mostly of symptom management, i.e., the 
reduction of pain and improvement of joint function with 
conventional treatment methods such as the use of anal-
gesics or non-steroidal anti-inflammatory drugs [2, 3]. 
Recently, the failure of these conventional treatments has 
given rise to the increasing use of symptomatic slow-act-
ing drugs for OA (SYSADOA)-based therapies.
One of the commonly used SYSADOAs is glucosamine 
[4]. Glucosamine, an amino monosaccharide, is an indis-
pensable component of chondroitin sulfate and keratin 
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sulfate, which are the main glycosaminoglycans (GAG) 
in the cartilage [5, 6]. Glucosamine has been used in the 
supplementary treatment of OA, although its effects on 
the extracellular matrix (ECM) metabolism in chondro-
cytes remain controversial [7, 8]. In chondrocyte pellet 
culture, glucosamine acts as a suppressor of interleu-
kin-1 (IL-1)-induced prostaglandin E2 synthase and 
stimulates proteoglycan synthesis [9–11]. Administra-
tion of glucosamine in a chymopapain-induced damaged 
rabbit joint [12] and murine OA model [13] resulted in 
increased cartilage matrix. Moreover, the investiga-
tors reported mild protection efficacy of glucosamine 
in human articular cartilage, including the reduction of 
surface fibrillation, loss of safranin O staining, and loss of 
sulfated glycosaminoglycans [14]. In 2013, Caramés et al. 
demonstrated the therapeutic efficacy of glucosamine 
in OA by providing evidence that it activated autophagy 
by inhibiting the AKT/FoxO3/mammalian target of the 
rapamycin pathway [15]. They suggested that a specific 
form of autophagy, mitophagy, could remove the dam-
aged mitochondria frequently observed in OA cartilage.
On the other hand, in 2014, Jiang et al. highlighted the 
negative effect of autophagic cell death in articular chon-
drocytes [16]. They observed that high concentrations of 
glucosamine had a negative effect on cell viability, possi-
bly due to autophagic cell death.
To date, a dual role for glucosamine has been implied, 
i.e., a potentially desired chondro-protective effect and 
an undesired negative effect. Therefore, in studying the 
effects of glucosamine, particular attention should be 
paid to the regulatory signals and molecules responsible 
for these dual functions. Here, we attempt to elucidate 
the underlying regulatory mechanisms that may deter-
mine the switch between these two possible opposing 
functions.
Although chondrocytes reportedly produce only 25 % of 
their total ATP via oxidative phosphorylation (OXPHOS) 
[17], recent studies have demonstrated that, in humans, 
OA chondrocytes demonstrated lower activity of mito-
chondrial respiratory chain complexes I, II, and III than 
normal chondrocytes [18]. In addition, this mitochondrial 
dysfunction may further affect the pathophysiological fea-
tures of OA, such as cartilage degradation, via reduced 
chondrocyte biosynthesis and growth, cartilage matrix cal-
cification, and increased chondrocyte apoptosis and inflam-
matory responses. Moreover, inflammatory cytokines such 
as TNF-α and IL-1β decrease ATP levels and mitochondrial 
membrane potential [19]. Taken together, these reports 
suggest that mitochondrial damage may play a significant 
role in the pathogenesis of OA. Recently, we suggested the 
possible functional interconnection between mitochon-
dria and peroxisome [20], i.e., peroxisomal dysfunction 
may trigger mitochondrial dysfunction in human articular 
chondrocytes. However, these functional interconnections 
during OA pathogenesis remain poorly understood and 
need to be further characterized. In the present study, we 
investigated the dual functions of glucosamine in human 
articular chondrocytes and assessed whether peroxisomal 
dysfunction may play a role in regulating these glucosamine-
induced beneficial and disadvantageous functions.
Methods
Cell line and cell culture
Human chondrocytes derived from normal human artic-
ular cartilage were purchased from Cell Applications (San 
Diego, CA). Cells were cultured in chondrocyte growth 
medium (Cell Applications). Cells were maintained in a 
humidified incubator at 37 °C with 5 % CO2. To check the 
differential ability of chondrocytes, pellet cultures were 
applied and stained with Alcian blue and the RNA levels 
of type II collagen and aggrecan were analyzed before the 
experiments. For this study, cells were treated with 10, 30, 
50 and 100 mM d-(+)-glucosamine hydrochloride for 2 h 
(short time exposure) or 24 h (long time exposure) unless 
exposure time is indicated, respectively (Sigma-Aldrich, 
St. Louis, MO, dissolved in growth media).
Pellet culture of chondrocytes
For differentiation, alginate beads with encapsulated 
human chondrocytes (Cell applications, San Diego, 
CA, USA) were grown in a chondrocyte differentiation 
medium (Cell applications, San Diego, CA, USA) for 
2 weeks. Briefly, human chondrocyte were suspended at a 
density of 4 × 106 per milliliters in a 1.2 % solution of ster-
ile alginate in 0.15 M NaCl. The cell suspension was slowly 
expressed through a 22-gauge needle and dropped into a 
102-mM CaCl2 solution. The beads with approximately 
40,000 cells/bead (diameter 3 mm) were allowed to polym-
erize for 10 min and washed twice with 0.15 M NaCl, fol-
lowed by two washes in DMEM/F12. The beads were then 
transferred to medium and cultured at 37 °C in a humidi-
fied atmosphere of 5 % CO2. Alcian blue staining was used 
to detect chondrocyte nodule formation after 2 weeks of 
alginate beads culture. Alginate beads were rinsed with 
PBS and fixed in 4 % paraformaldehyde in PBS for 20 min. 
Alginate Beads were washed with PBS three times and 
stained in 1 % Alcian blue in 0.1 N HCl for 8 h at room 
temperature. Alginate Beads were de-stained in 0.1 N HCl 
two times and stored in water for image capture.
Quantitative real‑time PCR (qRT‑PCR)
Total RNA was isolated using RNAiso Plus (TaKaRa, 
Japan) according to the manufacturer’s protocol. Ali-
quots of total RNA (1 μg) from each sample were reverse-
transcribed into cDNA according to the instructions of 
the PrimeScript 1st strand cDNA Synthesis Kit (TaKaRa, 
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Japan). Quantitative real-time PCR (qRT-PCR) was per-
formed using the StepOnePlus Real-Time PCR System 
(Applied Biosystems, Foster City, CA, USA). PCR were 
prepared and heated to 95  °C for 2  min followed by 40 
cycles of denaturation at 95  °C for 15  s, annealing at spe-
cific Tm for 15 s, and extension at 72 °C for 20 s. Quanti-
fication of the PCR signals was achieved by comparing the 
cycle threshold value (Ct) of the gene of interest with the Ct 
value of the reference gene GAPDH. The following oligo-
nucleotides were used as primers: MMP13: 5′-TTGCAG 
AGCGCTACCTGAGATCAT-3′, antisense, 5′-TTTGC 
CAGTCACCT CTAAGCCGAA-3′, sense; ADAMTS4: 
5′-CGCTTTGCTTCACTGAGTAGAT-3′, antisense, 5′-CT 
GTTAGCAGGTAGCGCTTTAG-3′, sense; PMP70: 5′- C 
CAGTTGGGTCATATCCT TGAA-3′, antisense, 5′- CTT 
GCCATCGCC ATTCTTTG-3′, sense; LC3A: 5′- ACA 
GCATGG TGAGTGTGTC-3′, antisense, 5′- GGGAGG 
CGTAGACCATATAGA-3′, sense; LC3B: 5′- GCCTTC 
TTCCTGTTGGTGAA-3′, antisense, 5′- TGGGAGGCAT 
AGACCATGTA-3′, sense; CASP1: 5′-GGCAGGCCTGGA 
TGATGA-3′, antisense, 5′-ATACCAAGAACT GCCC 
AAGTTTG-3′, sense, CASP3: 5′-GCGCCCTGGCAGC 
AT-3′, antisense, 5′-GCCTACAGCCCATTTCTCCAT-3′ 
sense, CASP9: 5′-AACAGCATTAGCGACCCTAAGC-3′ 
antisense, 5′-AGCAGTGGGCTCAC TCTGAAG-3′, sense, 
FAS: 5′-CCAGCATGG TTGTTGAGCAA-3′ antisense, 
5′-ACCCGCTCAGTACGGAGTTG-3′, sense, COMP: 
5′-TCACAAGCATCTCCCACAAA-3′ antisense, 5′-GAC 
AGTGATGGCGATGGTATAG-3′ sense, ACAN: 5′-TCG 
AGGGTGT AGCGTGTAGAGA-3′ antisense, 5′-TCGAG 
GACA GCGAGGCC-3′ sense, GAPDH: 5′-GATCATCAG 
CAATGCCTCCT-3′, antisense, 5′-TGTGGTCATG AGT 
CCT TCCA-3′, sense.
Annexin V and viability cell assays
The apoptotic and necrotic cell populations were ana-
lyzed by Muse Cell Analyzer (Merck Millipore), which is 
a miniaturized fluorescent flow cytometer. Analyses were 
performed using specific fluorescent dyes Muse Annexin 
V and Dead Cell Kit (Merck Millipore). Briefly, both 
floating and adherent treated cells were collected, centri-
fuged at 300×g for 5  min, and suspended in phosphate 
buffered saline (PBS). Aliquots of 100 μL of cell suspen-
sion were added to 100  μL of diluted Muse Annexin V 
and Dead Cell reagent and incubated for 20 min at room 
temperature (RT). Subsequently, cells were analyzed and 
the percentage of early or late apoptotic cells was deter-
mined in accordance with the Millipore guidelines.
Mitochondrial membrane potential assay
The mitochondrial depolarization state of cells was ana-
lyzed by Muse Cell Analyzer (Merck Millipore). We 
simultaneously measured changes in the mitochondrial 
membrane potential by assay kit (Merck Millipore). 
Briefly, both floating and adherent treated cells were col-
lected, centrifuged at 300×g for 5  min, and suspended 
in cell culture medium. Briefly, 100  μL aliquots of cell 
suspension were first added to 95  μL of diluted Muse 
Mitopotential dye and mixed for 20 min at 37 °C before 
incubating with 5 μL of 7-AAD reagent dye at RT. After 
5  min, the cell suspensions were analyzed and the per-
centages of live, depolarized, and dead cells were deter-
mined in accordance with the Millipore guidelines.
BODIPY staining
BODIPY 493/503 or BODIPY 665/676 (Molecular 
Probes, Carlsbad, CA, USA), was diluted in PBS at a 
concentration of 1  mg/mL. Following fixation with 4  % 
paraformaldehyde (PFA) for 10  min and staining with 
4,6-diamidino-2-phenylindole (DAPI) for identifica-
tion of nuclei, the samples were washed 3 times in PBS 
for 10 min and stained with BODIPY. The samples were 
mounted in VECTASHIELD (Vector Laboratories), 
covered with glass cover slips, and digital images were 
obtained with an Olympus Fluoview FV100 confocal 
laser scanning microscope under epifluorescent optics.
Tandem fluorochrome pexophagy assay
Human chondrocytes were transfected with the mRFP-
EGFP-SKL plasmid. Two days after the first transfection, 
the cells were cultured for another 24 h in the presence of 
lysosomal inhibitors, 120 μM leupeptin (Sigma-Aldrich), 
and 2 μM E-64 (Enzo Life Sciences). After incubation, the 
cells were washed in PBS and fixed with 4 % PFA in PBS 
for 15 min at RT.
LC3‑positive vesicle formation
Human chondrocytes were transfected with LC3-GFP 
plasmid. Transfection efficiency of the plasmid was 
assessed visually (>60 % and identical for all wells). After 
2 days, the cells were starved for 3 h in the presence of 
20 μM chloroquine (InvivoGen) and permeabilized with 
0.025 % digitonin in PBS for 5 min to wash out the cyto-
solic LC3 protein and enrich for the vesicle-associated 
LC3. Subsequently, the cells were washed in PBS and 
fixed with 4 % PFA in PBS for 15 min at RT.
Gas chromatography/mass spectrometry
Total lipids were extracted using a chloroform/methanol 
(2:1 v/v) mixture. The extracted lipids were separated on 
a Sep-Pak Silica Cartilage column (Waters, Milford, MA, 
USA) and transmethylated with 0.5 M CH3ONa in meth-
anol by heating in a sealed tube at 70  °C for 1  h under 
nitrogen. The fatty acid methyl esters were extracted with 
hexane. Subsequent gas chromatography–mass spec-
trometry (GC–mass) analysis was performed according 
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to the standard protocol. Briefly, the sample was injected 
into a Finnigan MAT-8430 mass spectrometer con-
nected to an HP-5890 gas chromatography (Finnigan 
MAT, Bremen, Germany) equipped with a DB-5 capillary 
column.
Apoptosis and autophagy profiling PCR array
Apoptosis and autophagy profiling was conducted using 
the RT2 Profiler PCR Array Kit (QIAGEN, GmbH, 
Hilden, Germany), which included specific primers for 
apoptosis (PAHS-012Z) or autophagy (PAHS-084Z). 
Each profiling array was performed according to the 
manufacturer’s instructions. cDNA was synthesized with 
the RT2 First Strand Kit (Qiagen, #330401) and qRT-PCR 
was performed using the RT2 qPCR SYBR Green Fluor 
qPCR Master Mix (Qiagen, #330512) according to the 
manufacturer’s instructions. Data were analyzed and 
gene expression data visualized using GenEx (Weihenste-
phan, Germany).
Western Blot
Cells were lysed in RIPA buffer (50  mM Tris–HCl, 
pH 7.4, containing 150  mM NaCl, 1  % Nonidet P-40, 
0.1 % SDS, 0.1 % deoxycholic acid, 10 mM NaF, 10 mM 
Na4P2O7, 0.4  mM Na3VO4, and protease inhibitors) for 
30 min on ice. The total protein content of the cells was 
determined by BCA Protein Acid Reagent (bicinchoninic 
acid) (Pierce Biotechnology Inc., Rockford, MN, USA). 
Proteins (30 μg) were separated by 10 % polyacrylamide 
gel electrophoresis containing 0.1 % SDS and transferred 
to nitrocellulose membranes (GE Healthcare Life Sci-
ences, Uppsala, Sweden). The membranes were incu-
bated for 1  h at room temperature in a blocking buffer 
(20  mM Tris–HCl, 137  mM NaCl, pH 8.0, containing 
0.1  % Tween and 3  % skimmed dry milk), and probed 
with antibodies against Beclin, LC-3B and GAPDH (Cell 
Signaling, Beverly, MA, USA). The blots were developed 
with an HRP-conjugated secondary antibody and reacted 
proteins were visualized using an electrochemilumines-
cence (ECL) system (GE Healthcare Life Sciences).
Results
High‑dose glucosamine induces pathological 
characteristics of OA
Human articular chondrocytes were cultured in growth 
media and their chondrogenic capacity analyzed. Pel-
let culture of human chondrocytes showed an increase 
in Alcian blue staining and the transcription of a well-
known cartilage matrix, cartilage oligomeric matrix 
protein (COMP) was increased as culture progressed. 
As previously mentioned [17–20], there is a significant 
controversial opinion on glucosamine effect, particu-
larly with high dose of glucosamine. To verify the role 
of high-dose glucosamine in OA pathogenesis, chon-
drocytes were treated with increasing doses of glucosa-
mine (10–100  mM). The number of chondrocytes was 
presenting severely degenerative morphology under 
glucosamine treatment and this degeneration was wors-
ening in a dose-dependent manner (Fig.  1a). Consistent 
with morphological changes, the RNA levels of MMP-13 
and ADAMTS4 were significantly increased in 50  mM-
treated chondrocytes (Fig. 1b). To investigate the involve-
ment of chondrocyte apoptosis in high-dose treatment 
of glucosamine, cells were stained with annexin-V/PI 
and analyzed by flow cytometry. After treatment with 
glucosamine for 24  h, the population of cells indicated 
a shift from viable cells to early and late stage apoptosis 
in a dose-dependent manner (Fig.  1c). The average per-
centage of late apoptotic cell populations increased to 
15.25 and 19.54 %, respectively, for cells treated with 50 
or 100  mM glucosamine suggesting that high dose of 
glucosamine may trigger chondrocyte apoptosis. Since 
mitochondrial dysfunction is closely related to cell death, 
we further assessed alterations in mitochondria poten-
tial (Fig. 1d). The average percentage of depolarized dead 
cells increased to 34.5 and 38.9 %, respectively, for cells 
treated with 50 or 100 mM glucosamine.
High‑dose glucosamine induced peroxisome dysfunction 
and accumulation of very long chain fatty acids (VLCFA)
Recently, our laboratory suggested an interconnec-
tion between mitochondria and peroxisome during OA 
pathogenesis [20]. To investigate whether high-dose glu-
cosamine induced peroxisomal dysfunction as well as 
mitochondrial dysfunction, normal chondrocytes were 
stained with BODIPY (493/503). We found that signifi-
cantly large amounts of lipid were accumulated in cells 
treated with 50 and 100  mM glucosamine (Fig.  2a, left 
panel), indicating a possibility that high-dose glucosa-
mine may induce dysfunction of peroxisome. To evaluate 
peroxisomal function, we determined the expression lev-
els of PMP70/ABCD3, a70  kDa peroxisomal membrane 
protein and acyl-CoA oxidase 1 (ACOX1), which cata-
lyzes the first step of peroxisomal fatty acid β-oxidation 
by qRT-PCR (Fig.  2b). The expression levels of PMP70 
and ACOX1 were significantly decreased in cells treated 
with either 50 or 100 mM glucosamine.
Next, we investigates the possibility that this peroxi-
somal dysfunction by glucosamine could be resulted in 
lipid accumulation due to lipid metabolism impairment. 
Lipidomics analysis (Table 1) showed that treatment with 
50  mM glucosamine lead to the accumulation of very 
long chain fatty acids (VLCFA) in normal chondrocytes 
(Fig. 3a). By adding exogenous lignoceric acid to the cells, 
we evaluated the effects of VLCFA on lipid metabolism. 
Cells treated with VLCFA showed a severely degenerative 
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morphology (Fig.  3b, upper panel). Furthermore, cells 
treated with lignoceric acid demonstrated significantly 
increased MMP-13 RNA levels (Fig.  3b, lower panel). 
Moreover, levels of pro-apoptotic genes including FASL, 
FAS and BAX, as well as the percentage of apoptotic cell 
populations, were increased with lignoceric acid treat-
ment (Fig. 3c). These data suggest that high-dose glucosa-
mine-induced VLCFA accumulation may be responsible 
for chondrocyte apoptosis and MMP-13 induction.
High‑dose glucosamine stimulates autophagic cell death
To evaluate whether autophagic cell death is involved in 
glucosamine-induced apoptosis, the expression levels 
of genes involved in apoptosis (Fig.  4a) and autophagy 
(Fig.  4b) were analyzed. Both levels of apoptotic genes 
and autophagic genes assessed here were significantly 
increased to more than threefold in cells treated with 
50 mM glucosamine. RNA levels of caspase-1, -3, -6, -7, 
and -9 demonstrated a 15.5-, 9.8-, 9.7-, 13.2-, and 10.9-
fold increase, respectively (Fig. 4a). RNA levels of ATG3, 
ATG5, ATG7, ATG12, and ATG16L1 showed a 3.6-, 7.4-, 
12.3-, 5.2-, and 12.2-fold increase, respectively (Fig. 4b). 
Moreover, expression levels of beclin-1 were increased 
4.3-fold in cells treated with 50  mM glucosamine. To 
confirm that glucosamine induced the hyper-activation 
of autophagic response, normal chondrocytes were 
treated with glucosamine in the absence or presence of 
MG132, a cell-permeable proteasome inhibitor. In the 
presence of MG132, the cells exposed to glucosamine 
showed slightly decreased levels of autophagy markers 
becin-1 and LC-3B, suggesting that the treatment with 
high-dose glucosamine may actually decrease autophagic 
responses (Fig.  4c). In addition, the pattern of microtu-
bule-associated LC3, as assessed by immunostaining, 
indicated inactivation of autophagic response under glu-
cosamine treatment (Fig. 4d, upper panel). Next, we used 
the tandem fluorochrome pexophagy assay with mRFP-
EGFP-SKL as a reporter. Cells treated with glucosamine 
did not display the characteristic “red only” structure as 
a consequence of EGFP fluorescence quenching by acid 
Fig. 1 Effect of glucosamine in human normal chondrocytes. a Normal chondrocytes were cultured as a pellet and stained with Alcian blue at 
day 9 and the expression levels of COMP and ACAN were analyzed by qRT‑PCR to check chondrogenic characteristics (left panel). Normal human 
chondrocytes were left untreated or were treated with 10, 50 or 100 mM glucosamine for 24  h. A dose‑dependent change in the cell morphology 
was detected by phase‑contrast microscopy (right panel). b RNA levels of MMP‑13 and ADAMTS4 were analyzed by qRT‑PCR. Cells were analyzed 
by c Muse™ Annexin V and Dead Cell assay and d Muse™ Mitopotential assay. Bars show the mean ± SD of three individual experiments. *P < 0.05 
versus control (untreated)
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pH after the delivery of peroxisome to lysosome, which 
would indicate the stimulation of autophagic responses 
(Fig. 4d, lower panel).
As mentioned earlier, the effect of glucosamine in OA 
is still controversial. Whilst some reports showed that 
high-dose glucosamine may stop the degradation of car-
tilage by acting as a chondro-protective agent [21], others 
have reported a negative effect of high-dose glucosamine 
during OA pathogenesis [22], suggesting the possibility 
that the effects of glucosamine may depend on treatment 
length or duration. Therefore, we analyzed microscopy-
based GFP-LC3 puncta formation in cells exposed to 
50 mM glucosamine, to address this possibility. At expo-
sure times of 2 h (short time exposure), glucosamine was 
found to induce GFP-LC3 puncta. However, glucosamine 
significantly suppressed GFP-LC3 puncta at 24  h expo-
sure (Fig. 5a). Next, we analyzed whether the difference 
in the effects of glucosamine based on the exposure time 
(short time exposure vs. long time exposure) is a result 
of peroxisomal dysfunction. Peroxisomal oxidation was 
not affected during short time exposure of glucosamine, 
although during long time exposure of glucosamine, we 
observed a significant reduction in peroxisomal oxidation 
(Fig.  5b). Consistent with these findings, the expression 
levels of acyl-CoA-binding protein (ACBD5), a typical 
marker for pexophagy, or acyl-CoA oxidase 1 (Acox-1), 
an initial enzyme in β-oxidation, increased during short 
time exposure of glucosamine but decreased during long 
time exposure. A typical cartilage matrix gene, COMP 
was dramatically decreased during short time exposure 
(Fig.  5c). Moreover, when normal chondrocyte were 
exposed with low concentration, we found that 5  mM 
glucosamine increased transcription of cartilage matrix 
gene, COMP and suppressed apoptotic genes such as 
CASP1 and FAS (Fig. 6).
Discussion
Glucosamine is the main component of proteoglycans, 
and the major non-collagenous cartilage-specific proteo-
glycan of the intervertebral disc is aggrecan. In the clinic, 
glucosamine has been used in the treatment of OA, 
although the application has not been widely accepted 
Fig. 2 Effect of glucosamine on peroxisomal function. Normal human chondrocytes were left untreated or were treated with 10, 50, or 100 mM 
glucosamine for 24 h. a Cells were stained with BODIPY 493/503 and PMP70. b The RNA levels of PMP70 and ACOX1 were analyzed by qRT‑PCR. 
*P < 0.05 versus control (untreated)
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Table 1 Lipidomics of glucosamine-treated chondrocytes
Control Glucosamine 10 mM Glucosamine 50 mM
Name % Name % Name %
Nonahexacontanoic acid 0.07 Nonahexacontanoic acid 0.042 0.125
Tetratetracontane 0.21 Glycerol tristearate 0.518 Nonahexacontanoic acid 0.17
Hentriacontane 0.04 Cholesta‑3,5‑diene 0.304 Benzenepropanoic acid,3,5‑bis(1,1‑
dimethylethyl)‑4‑hydroxy‑
0.197
Cholesta‑3,5‑diene 0.12 2,4,6‑Triphenyl‑1‑hexene‑D5 3.155 Cholesta‑3,5‑diene 0.124
Hexacosane 0.07 Docosane 0.393 Tetracosane 2.598
2,4,6‑Triphenyl‑1‑hexene 3.09 rac Methadone N‑oxide 0.288 Dioctyl terephthalate 2.483
tricosane 0.08 Eicosane 5.42 2,4,6‑Triphenyl‑1‑hexene‑D5 0.28
Docosane 0.5 Eicosanoic acid 0.849 Docosane 13.003
cis‑4,7,10,13,16,19‑Docosahexaenoic acid 0.14 Methyl arachidonate 0.122 Erucylamide 0.612




0.046 Glycerol b‑monostearate 0.06
Nonadecyl trifluoroacetate 0.06 1‑Nonadecanol 0.196 1‑Dodecanol, 2‑octyl‑ eicosane 1.733
Eicosane 3.32 2‑Hexadecanoyl glycerol 0.877 5,8,11,14,17‑Eicosatetraenoic acid 0.152
Eicosanoic acid 0.83 Methyl linoleate 0.112 Nonadecane 0.08
Arachidonic acid 0.41 Octadecanoic acid 1.746 2‑Hexadecanoyl glycerol 1.397
5,8,11,14,17‑Eicosapentaenoic acid 0.09 1‑Octadecene 0.115 1‑Nonadecene 0.094
Hexadecanoic acid,2‑hydroxy‑1‑
(hydroxymethyl) ethyl ester
1.39 9‑Octadecenamide, (Z)‑ 4.827 Octadecanoic acid 1.556
Methyl 9‑(Z)‑octadecenoate 1.12 11‑Octadecenoic acid,(11Z)‑ 0.094 9‑Octadecenamide, (Z)‑ 0.91
9,12‑Octadecadienoic acid (Z,Z)‑, methyl 
ester
0.31 Palmitic acid 1.343 Linoleic acid 0.141
Thiocarbamic acid 0.28 2‑Propenoic caid, tridecyl ester 0.465 11‑Octadecenoic acid,(11Z)‑ 0.386
Octadecane 0.15 Hypogeic acid 0.35 trans‑9‑octadecenoic acid 0.091
Stearic acid 2.21 [2.2]Paracyclophane 0.059 Pentafluoropropionic acid tetradecyl ester 0.136
1‑Octadecene 0.11 3‑Methyl‑2‑benzylindole 4.12 2‑Ethylhexyl methyl isophthalate 0.065
9‑Octadecenamide, (Z)‑ 5.98 2,4‑Diphenyl‑1‑butene‑D5 0.437 1‑Decanol,2‑hexyl‑ 0.059
Heptafluorobutyric acid, n‑tetradecyl ester 0.18 1‑Pentadecene 0.129 Hexadecane 0.142
Methyl hexadecanoate 1.68 2‑Methyl‑1‑anthracenamine 6.432 Palmitic acid 1.374
Cyclopentolate 0.14 1‑Methyl‑2‑anthracenamine 2.094 Benzene,1,1′‑(1,2‑cyclobutanediyl)bis‑, 
trans‑
0.28
Fumaric acid, 2‑ethylhexyl hexyl ester 0.11 Tetradecane 0.125 3‑Methyl‑2‑benzylindole 5.108
Hexadecane 0.07 2‑Tetradecene 0.162 2,4‑Diphenyl‑1‑butene‑D5 0.337
Hexadecanoic acid 0.33 Phenol,2,5‑bis(1,1‑dimethylethyl)‑ 0.079 1,3‑diphenyl‑cyclobutane 0.06
2‑Propenoic acid, tridecyl ester 1.41 5‑Methoxy‑2‑methyl‑1‑propyl‑1H‑indole‑
3‑carboxylic acid




Benzene,1,1′‑(1,2‑cyclobutanediyl)bis‑, cis‑ 0.37 Sulfurous acid, dodecyl 2‑propyl ester 0.155 1H‑Indole,2‑methyl‑3‑phenyl‑ 1.934
3‑Methyl‑2‑benzylindole 4.11 Dodecane 0.115 2‑Ethylacridin 0.553
Cyclobutane,1,3‑diphenyl‑,trans 0.06 Cyclododecane 0.12 Benzo[h]quinoline,2,4‑dimethyl‑ 0.113
Propanoic acid,3‑mercapto‑, dodecyl ester 0.66 1‑Methyl‑5,6‑dimethoxy‑2,3‑dihydroindole 2.373 Tridecane, 6‑methyl‑ 0.164
Benzene,1,1′‑(1,3‑propanediyl)bis‑ 0.07 2,7‑Naphthalenedisulfonicacid, 3‑hydroxy‑
4‑nitroso‑
0.37 Tetradecane 0.084
1‑Methyl‑2‑anthracenamine 4.45 1‑Decene 0.191 2,4‑Di‑tert‑butylphenol 0.094
1‑Tetradecanol 0.24 2‑Methylmercaptobenzothiazole 0.498 Benzene,1,3‑bis(1,1‑dimethylethyl)‑ 0.152
Tetradecane 0.12 1,4‑Benzenedicarboxylic acid 3.412 12‑Hydroxydodecanoic acid 0.224
2,4‑Di‑tert‑butylphenol 0.13 Benzene 0.19 2‑Propenoic acid oxybis(methyl‑2,1‑ethan‑
ediyl) ester
0.699
2‑Tridecanone 0.17 Fumaric acid 0.08 Ethyl 4‑etoxybenzoate 0.074
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Table 1 continued
Control Glucosamine 10 mM Glucosamine 50 mM
Name % Name % Name %
Dodecahydropyrido[1,2‑b]isoquinolin‑
6‑one
0.06 2‑Chloropropionic acid 0.069 Cycl zodecane 0.249
Decane, 2, 3, 5‑trimethyl 0.16 exo‑5‑hydroxy‑exo‑2,3,3a,4,5,6,7,7a‑octahy‑
dro‑4,7‑methano‑1H‑indene
0.079

















Carbonochloridic acid, decyl ester 0.16
Fig. 3 Effect of glucosamine on VLCFA. a Normal human chondrocytes were left untreated or were treated with 10 and 50 mM glucosamine for 
24  h. Total lipid was analyzed using gas chromatography/mass spectrometry and divided into LLCFA, LCFA, MCFA, and SCFA. b Normal human 
chondrocytes were left untreated or were treated with lignoceric acid (VLCFA) for 24 h and cell morphologies were assessed by phase‑contrast 
microscopy (upper panel). RNA levels of MMP‑13 were analyzed by qRT‑PCR (lower panel). c RNA levels of pro‑apoptotic genes were analyzed by 
qRT‑PCR and presented as heat‑map. Red color represented as significant increase in expression levels. Apoptotic cell populations were analyzed by 
FACS. Bars show the mean ± SD of three individual experiments. *P < 0.05 versus control (untreated)
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and remains controversial [7, 8]. In this study, we dem-
onstrated that glucosamine could act differently depend-
ing on its dosage and period of treatment. Exposure of 
chondrocytes to high-dose glucosamine induced lipid 
accumulation, possibly through suppression of PMP70 
and ACOX1, and resulted in the stimulation of cell death, 
thus indicating a regulatory role for glucosamine in per-
oxisomal function. Since the peroxisome is involved in 
lipid metabolism, including β-oxidation of fatty acids and 
transfer of oxidized lipid to mitochondria for utilization 
in energy metabolism [23–25], peroxisomal dysfunction 
could be a trigger for OA-induced chondrocyte death.
One of the typical characteristics in OA pathogenesis 
is chondrocyte apoptosis in cartilage, but the underly-
ing regulatory mechanisms have not been well studied. 
Recently, nitric oxide (NO) and reactive oxygen species 
(ROS) have been suggested to be key factors in medi-
ating chondrocyte apoptosis through mitochondrial 
dysfunction such as damage of mitochondrial DNA [26]. 
Impairment of mitochondrial events have been known to 
be involved in chondrocyte apoptosis, including reduc-
tion of the mitochondrial transmembrane protein com-
plex IV, decrease of mitochondrial membrane potentials 
and release of cytochrome c [27]. In the present report, 
we observed that long-term exposure to glucosamine 
induced impairment of mitochondrial membrane poten-
tials, suggesting the involvement of glucosamine in 
the regulation of mitochondrial function during OA 
pathogenesis.
Recently, other and our group have provided evi-
dence for an interconnection between cellular orga-
nelles, particularly between the mitochondria and the 
peroxisome. Peroxisome dysfunction hindered mito-
chondrial function and vice versa. Likewise, we also 
found in this study that glucosamine induced dysfunc-
tion of mitochondria as well as that of the peroxisome 
Fig. 4 Effect of glucosamine on autophagy in human normal chondrocytes. Normal human chondrocytes were treated with 50 mM glucosamine 
and the RNA levels of a pro‑apoptotic genes and b autophagy‑related genes were analyzed by qRT‑PCR and expressed as a heat‑map and value of 
relative quantity (RQ). c Normal human chondrocytes were treated with 10, 50, or 100 mM glucosamine in the absence or presence of MG132 and 
the dose‑dependent change in protein levels of beclin and LC3B was detected by immunoblotting. GAPDH was used as a loading control.  
d Normal human chondrocytes were treated with 50 mM glucosamine and pexophagy was examined by introducing an mRFP‑EGFR‑SKL construct. 
Results shown are representative of at least four independent experiments. *P < 0.05 versus control (untreated)
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Fig. 5 Effect of short time exposure vs. long time exposure of glucosamine. a Normal human chondrocytes were treated with 50 mM glucosa‑
mine for 2 or 24 h and the autophagosome formation was analyzed by introducing LC3‑GFP constructs. b Normal human chondrocytes were left 
untreated or were treated with 10, 30, 50, or 100 mM glucosamine for 2 or 24 h. Cell morphology was detected by phase‑contrast microscopy and 
peroxidation was analyzed by BODIPY 665/676 staining (upper panel). The RNA levels of ACBD5 and ACOX1 were analyzed by qRT‑PCR (lower panel). 
Results shown are representative of at least four independent experiments. c RNA levels of COMP and ACAN were analyzed by qRT‑PCR. Results 
shown are representative of at least four independent experiments
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in human chondrocytes. Long-term exposure to glu-
cosamine induced the accumulation of VLCFA and 
this could be responsible for chondrocyte apoptosis. 
Recent studies showed a correlation between VLCFA 
accumulation and cell death as a result of the silenc-
ing of peroxisomal transporters and altered mito-
chondrial function [28]. ABCD-1 deficiency induced 
apoptosis in oligodendrocytes and led to astrocytic 
inflammatory responses and loss of myelin [29, 30]. In 
addition, VLCFA depletion is known to result in con-
stitutive activation of autophagy [31], indicating that 
VLCFAs serve to dampen the amplitude of autophagy. 
VLCFA accumulation induced by long-term exposure 
to glucosamine could be responsible for suppression of 
autophagic responses in OA chondrocytes. This sug-
gests that the functional integrity of peroxisomes in the 
regulation of VLCFA has important implications for 
autophagy and cell homeostasis.
Further, we described, for the first time, a direct corre-
lation between glucosamine and pexophagy. Even though 
glucosamine is widely used to treat or prevent OA in 
humans, the effects of treatment on cartilage degen-
eration are controversial. We showed that glucosamine 
exhibits a concentration- and exposure time-dependent 
dual action in the regulation of chondrocyte survival and 
apoptosis. Recent research on an association between 
glucosamine and the PI3K/AKT/mTOR signaling path-
way has elicited controversial reports. Caramés et al. had 
demonstrated that the mTOR pathway was inhibited by 
glucosamine in chondrocytes [15]. In contrast, Shintani 
et  al. found that the mTOR pathway did not participate 
in glucosamine-induced autophagy in HeLa and COS7 
cells [32]. Here, short exposure of glucosamine acti-
vated autophagic responses (referred to as short time 
response), whereas long exposure of glucosamine inhib-
ited autophagic response, particularly pexophagy and led 
to impairment of peroxidation (referred to as long time 
response). Taken together, these results indicate that 
depending on the period of exposure, glucosamine may 
act as both a suppressor and inducer of apoptosis and 
autophagy.
Fig. 6 Effect of short time exposure vs. long time exposure of glucosamine. Normal human chondrocytes were cultured as monolayer or pellet and 
treated with 1, 3, or 10 mM glucosamine for 9 days. Cell morphology of monolayer culture was detected by phase‑contrast microscopy and pellet 
cultures were stained with Alcian blue at day 9 (upper panel). The expression levels of cartilage matrix genes such as COMP, ACAN and apoptotic 
genes such as CASP1, 3, 9, FAS were analyzed by qRT‑PCR. Results shown are representative of at least four independent experiments. *P < 0.05 
versus control (untreated)
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Conclusions
Collectively, our data demonstrated the role of glu-
cosamine in autophagy and showed a direct correlation 
between glucosamine and peroxisomal function. We 
also highlighted a dual role of glucosamine in apoptosis 
and autophagy in human chondrocytes. Glucosamine 
exerts exposure time-dependent dual effects on apopto-
sis and autophagy. Although further research is required 
to fully understand the relationship between dosage and 
exposure time to glucosamine, the differential opposing 
effects of glucosamine indicate that dosage and duration 
of treatment may be a determining factor in the line of 
beneficial reward-to-risk action in OA therapy.
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